Landiolol hydrochloride
CAS: 144481-98-1
Ref. TM-T5028
| 5mg | 51.00 € | ||
| 10mg | 65.00 € | ||
| 25mg | 93.00 € | ||
| 50mg | 134.00 € | ||
| 100mg | 173.00 € | ||
| 200mg | 237.00 € | ||
| 1ml*10 (DMSO) | 56.00 € |
Estimated delivery in United States, on Monday 13 May 2024
Product Information
Name:
Landiolol hydrochloride
Synonyms:
- ONO-1101 hydrochloride
- Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester, hydrochloride (1:1)
- Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester, monohydrochloride
- Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, monohydrochloride, [S-(R*,R*)]-
- Corebeta
- ONO 1101 hydrochloride
- Onoact
- Rapibloc
- [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-(4-{[(2S)-2-hydroxy-3-({2-[(morpholin-4-ylcarbonyl)amino]ethyl}amino)propyl]oxy}phenyl)propanoate hydrochloride (1:1)
- [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate hydrochloride
- See more synonyms
CAS:
Description:
Landiolol hydrochloride (ONO-1101 hydrochloride) is an ultra-short-acting β1 selective adrenoceptor antagonist.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
546.05
Formula:
C25H40ClN3O8
Purity:
99.75%
Color/Form:
White Crystalline Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T5028 Landiolol hydrochloride
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
